Mesenchymal stem cell (MSC) transplantation has been explored as a new clinical approach to repair injured tissue. A growing corpus of studies have highlighted two important aspects of MSC therapy: 1) MSCs can modulate T-cell-mediated immunological responses, and (2) systemically administered MSCs home to sites of ischemia or injury. In this review, we describe the known mechanisms of immunomodulation and homing of MSCs. First, we examine the low immunogenicity of MSCs and their antigen presentation capabilities. Next, we discuss the paracrine interactions between MSCs and innate [dendritic cells (DC)] and adaptive immune cells (T lymphocytes) with a focus on prostaglandin E 2 (PGE 2 ), indoleamine 2,3-dioxygenase (IDO), and toll-like receptor (TLR) signaling pathways. We transition to outline the steps of activation, rolling/ adhesion, and transmigration of MSCs into target tissues during inflammatory or ischemic conditions. These aspects of MSC grafts-immunomodulation and homing-are contextualized to understand a reported side effect of MSC therapy, cancer development.
INTRODUCTION
for the expression of surface markers such as CD73, CD90, and CD105, and the absence of expression of hematopoietic lineage markers (47). It is theorized that Within the bone marrow space multipotent stromal cells, also referred to as mesenchymal stem cells (MSCs), MSCs may reside in other locations other than the bone marrow, such as adipose tissue and surrounding vascula-are known to be the precursor cells for stromal tissues that support hematopoiesis (15) . MSCs are anchorage-ture structures, with the touted notion that they may be present in all adult tissues (13) . dependent cells, as opposed to other cells from bone marrow aspirates, thereby making their isolation fairly Although no specific surface marker or gene product to date distinguishes MSCs from other mesenchymal straightforward. More importantly, MSCs can expand rapidly in vitro while maintaining their multipotency (9) . cells, the functional properties of MSCs make them unique and therapeutically relevant. MSCs have been Many studies have demonstrated their therapeutic potential as multipotent cells (ability to differentiate into a shown to modulate immunological responses via T-cell suppression (1, 4, 19, 44, 59, 98) . As such, they have been limited number of cell types). Traditionally, MSCs can differentiate to mesenchymal lineages such as osteo-investigated as a new therapeutic strategy for T-cellmediated diseases such as graft-versus-host disease blasts, adipocytes, chondrocytes, and potentially other skeletal tissue cells by culturing MSCs in defined mech-(GVHD) (49,51), Crohn's disease (29) , and the prevention of organ transplantation rejection (10) . Moreover, anochemical conditions (72). MSCs are characterized 668 YAGI ET AL. the therapeutic benefit of MSC transplantation has been histocompatibility complex (MHC) molecules, including MHC class II (MHC-II), and the levels of MHC are al-observed in acute tissue injuries of the lung (68, 76) , heart (30, 67, 107) , kidney (45), and liver (33, 46, 100) . In tered by proinflammatory cytokines (4) . Previous studies have shown that low levels of IFN-γ cause MSCs to these disease contexts, MSCs have been observed to migrate to injured sites after systemic administration. Tis-express MHC-II as antigen-presenting cells (APCs) and high levels of IFN-γ mediate decreased expression of sue-specific engraftment is referred to as homing (2, 108) , and this aspect of MSC therapy in disease may be MHC-II (11) . Sheng et al. (86) describe a role for the IFN-γ-dependent expression of a negative costimulatory essential for their medicinal effects.
Herein, we present evidence that mechanistically molecule, B7-H1 (PD-L1), by MSCs. This study showed upregulation of PD-L1 by T-cell-mediated production of elaborates these two important components of MSC therapy: immunomodulation and homing. We discuss IFN-γ and the relevance of PD-L1 to the suppressive properties of MSCs. Taken together, a feedback loop how the natural functions of MSCs, such as antigen presentation and cytokine secretion, may impact immune may exist that alters MHC-II and PD-L1 expression by IFN-γ levels and ultimately coordinates the rise and fall cells during disease with a focus on several key molecular mediators and cellular targets of MSC therapy. We of an immune response. Hypothetically, when MSCs are exposed to an insult, such as a bacterial infection, MHC-transition then to understand the events associated with MSC trafficking and engraftment to injured tissues. Fi-II molecules facilitate the presentation of bacterial antigens, which leads to the activation of T cells. The latter nally, we leverage this understanding of MSCs to interpret a potential side effect of this cell therapy, namely cells produce IFN-γ. At high levels, IFN-γ mediates decreased expression of MHC-II to switch off antigen pre-cancer development.
sentation and concomitantly upregulate B7-H1, which MESENCHYMAL STEM CELLS inhibits activated T cells (Fig. 1 ). The roles of MSCs AND ANTIGEN PRESENTATION as both APCs and as immune suppressor cells can be explained as a function of IFN-γ levels and this balance The physical location, or niche, of a stem cell provides invaluable information of its role and interactions between the immune stimulatory and inhibitory properties should be considered for future clinical applications within the tissue. MSCs are reportedly located on the abluminal surface of the main sinusoidal blood vessels using MSCs. in the adult bone marrow, thus forming an interface be-EVIDENCE THAT MSCs tween the periphery and marrow cavity (5) . Because of ARE IMMUNOMODULATORY their location, cells entering or exiting the marrow may require engagement with MSCs. The "gatekeeping" as-
The ability of MSCs to modulate the immune system was first recognized after it was observed that they could pect of the MSC niche, along with the known immune properties of MSCs, suggests that MSCs are actively in-evade immunosurveillance after cell transplantation (52) . Now this ability of MSCs to alter an immune re-volved in homeostasis of bone marrow (74) as the first line of immunological defense. Because it would be de-sponse has been exploited for therapeutic purposes as by ongoing clinical trials of MSCs for the treatment of ste-sirable to rapidly clear insults to the bone marrow by infectious agents without overt inflammation, it should roid-refractory graft-versus-host disease (GVHD) (49). MSCs can suppress several T-lymphocyte activities be expected that MSCs may transition from immunostimulatory to immunosuppressive depending on the cir-both in vitro and in vivo (1, 4, 19, 44, 59, 98) . Naive and memory cells are subjected to MSC-mediated suppres-cumstance. Indeed, there is evidence to support the duality in MSC immune status. MSCs have been reported to sion and the MSC inhibitory effect does not require the presence of APCs and is not mediated through CD4 + / suppress immune rejection in different species (4, 18) . However, tolerance of MSCs across the allogeneic bar-CD25 + regulatory T cells (44) . Although the mechanisms by which these cells exert their immunosuppres-rier might not be absolute because studies by another group report on experimental evidence that questions the sive function are still unclear, it is likely that mechanisms involving both cell-to-cell contact and soluble status of immune privilege (22).
One potential route by which MSCs can naturally factors are involved in supporting T-cell inhibition in antigen-specific and nonspecific manners (1, 44, 59, 98) . switch immune states is based on the way they process antigens and express costimulatory molecules at the im-There are a number of cellular targets of MSC therapy that span both the innate and adaptive arms of the munological synapse. Furthermore, many studies have begun to elucidate what factors govern the immune state immune system. MSCs altered the cytokine secretion profile of dendritic cells (DCs), naive and effector T of MSCs and have revealed important roles for chemical cues, particularly interferon (IFN)-γ, in defining MSC cells [T helper 1 (TH1) and TH2], and natural killer (NK) cells to induce a more anti-inflammatory or toler-phenotype. MSCs have been reported to express major ant phenotype. Specifically, MSCs caused: 1) mature MSCs delivered by bolus injection of concentrated conditioned medium or by MSC extracorporeal bioreactor DCs type 1 (DC1) to decrease tumor necrosis factor-α (TNF-α) secretion and mature DC2 to increase interleu-treatment can reverse a rat model of multiorgan dysfunction syndrome (100). In contrast to those studies that kin-10 (IL-10) secretion; 2) TH1 cells to decrease IFNγ and caused TH2 cells to increase secretion of IL-4; 3) support a central role for MSC soluble factors others suggested that cell-cell contact is more important an increase in the proportion of regulatory T suppressor cells; and 4) decreased secretion of IFN-γ from NK (39, 89) . Tse et al. (98) demonstrated that close proximity to MSCs was important in suppressing T-cell respon-cells (1) . siveness and suggested that direct contact between lym-The Contribution of MSC Soluble Factors phocytes and MSCs was more important than soluble and Cell-Cell Interaction mediators in the immunosuppressive function of MSCs. Krampera et al. stated that inhibition requires the pres-Several studies have shown that MSCs actively inhibit the function of several immune cells through se-ence of MSCs in culture and MSC-T-cell contact (44) .
Recently, several reports stated the importance of com-creted cytokines, growth factors, and enzymatic action. For instance, the immunosuppressive function of lung bined soluble factors and cell-cell contact in MSCmediated immunosuppression (25,108). In order for resident MSCs was noted in the absence of direct cell contact (38) . Collectively, secreted molecules from MSCs to provide a pleiotropic immunomodulatory ef-fect that is responsive to different stimulants such as cy-eration. These findings support a model where IDO exerts its effect through the local accumulation of tryptophan tokines and chemokines and target different effector cells such as T cells, NK cells, and DCs, it seems rea-metabolites rather than through tryptophan depletion. However, Tse et al. (98) did not find a significant resto-sonable for MSCs to employ both direct and soluble mediators that coordinate for a multipronged approach to ration of proliferation by IDO. This finding indicates that IDO is not an exclusive mechanism for MSC immu-therapy. nomodulation in basal states, but it is essential for MSC suppression in the presence of IFN-γ.
Immunomodulation by Soluble Factors
The Role of Transforming Growth Factor-β (TGF-β),
MSC-Derived Lipid Intermediates Suppresses T-Cell
Hepatocyte Growth Factor (HGF), and Other Soluble Proliferation. Prostaglandin E 2 (PGE 2 ) is a lipid inter-Factors in MSC Immunotherapy. Previous studies demmediate that has been implicated as one of the potential onstrated that exposure to IFN-γ did not ablate MSC candidates responsible for T-cell inhibition by MSCs inhibition of T-cell proliferation, but induced expression (1, 25, 38) . Like all prostanoids, PGE 2 is synthesized from of HGF and TGF-β1 at concentrations that suppressed arachidonic acid via the actions of either the constitutive alloresponsiveness (79) . Another report demonstrated cyclooxygenase-1 (COX-1) or the inducible COX-2 enthat quantitative real-time PCR confirmed significant zyme (26) . Murine and human MSCs constitutively ex-HGF mRNA upregulated by IFN-γ and TNF-α (23). Di press COX-2. PGE 2 production is upregulated after Nicola et al. (19) suggested that HGF worked in synergy coculture of human MSCs with peripheral blood monowith TGF-β1 to resist T-cell recognition by simultanenuclear cells (PBMCs) (98), suggesting communication ous neutralization of HGF and TGF-β1 in the latter between MSC and lymphocytes that leads to the instudy restoring T-cell proliferation. In addition, there are creased production of immunosuppressive factors such several reports suggesting that other soluble factors such as PGE 2 (23,25). Both COX-2 and PGE 2 expression by as nitric oxide (83) 24), skewing of CD4 + T helper population dent (LR)-MSCs significantly inhibited proliferation of phenotypes, and modulation of CD8 + cytotoxic T lymthird party, HLA-mismatched T-cells, which was abrophocyte and NK cell functions (80) . NK cells are major gated by using COX inhibitors. These findings suggest effector cells of the innate immunity and are generally that PGE 2 is one of the key molecules involved in the thought to play a fundamental role in antiviral responses immunomodulatory effect of MSCs. (7) . MSCs and NK cells have been shown to interact in vitro (44, 89, 91) . The outcome of this interaction may MSC Metabolism of Tryptophan Suppresses T-Cell Proliferation. Recent data has shown a role for indole-depend on the state of NK cell activation and/or the cytokines present in the milieu. Previous studies have de-amine 2,3 deoxygenase (IDO) in human MSC-mediated immune suppression (59) . IDO is the rate-limiting en-scribed that cytokine-induced proliferation of NK cells was highly susceptible to MSC-mediated inhibition (91) . zyme involved in the catabolism of the essential amino acid tryptophan into its breakdown product kynurenine
In addition, the levels of surface expression of activating NK receptors were positively correlated with NK cell (95) . IDO is involved in the inhibition of T-cell proliferation by dendritic cells (34 Remarkably, the simultaneous onstrated the contribution of IDO to IFN-γ induced immunomodulation by MSC using an antagonist of IDO, blocking of IDO and PGE 2 could almost completely restore NK cell proliferation. They also showed the ability 1-methyl-L-tryptophan. Moreover, the tryptophan catabolite kynurenine had been examined in mixed lympho-of NK cells in killing target cells was markedly reduced when cultured with MSCs (90). These data further con-cyte reactions (MLR), and was found to block alloprolif-firm that IDO and PGE 2 may exert a synergistic effect implicated in controlling the expression of inflammatory cytokines and cell maturation molecules (53) . Pevsner-in the immunosuppressive activity mediated by MSCs.
Fischer et al. (71) demonstrated that cultured MSCs ex-DC Maturation. DCs play a key role in the initiation press TLR molecules 1 to 8. Activation of MSCs by of primary immune responses and in tolerance, depend-TLR ligands induced IL-6 secretion and NF-κB nuclear ing on the activation and maturation stage of DCs (3).
translocation. Liotta et al. (53) demonstrated that LPS Immature DCs behave as sentinels in peripheral tissues, was able to induce NF-κB activation in MSCs, as well with highly efficient antigen uptake and processing, and as cytokine and chemokine production such as IL-6, ILlow ability to stimulate T cells. Locally produced in-8, and CXCL10. However, the addition in culture of flammatory cytokines or microbial components promote LPS could significantly reduce the suppressive activity the maturation of DCs from a processing to a presenting of MSCs on T-cell proliferation. They showed that ligastage, characterized by upregulation of MHC class II tion of TLR3 or TLR4 on MSCs inhibited their supand costimulatory molecules (CD80 and CD86), producpressive effect on T-cell proliferation by hampering Jagtion of IL-12, and migration to lymphoid tissue (60) . DC ged-1 expression, which impaired signaling to its cognate maturation is a prerequisite to induce immunogenic T-Notch receptor expressed on T cells. TLRs were critical cell responses, whereas tolerance is observed when antiplayers in the immunoregulation observed in vivo when gens are presented by immature or semimature DCs MSCs were transplanted in vivo (41,97). The intersec-(23). Therefore, DC maturation plays a key role in inition of pathways triggered by IFN-γ was observed in the tiating T-cell responses (55) . Recent evidence demonimmunomodulatory effect of MSCs by the activation of strates that MSC disrupt the three major functions that NF-κB through the upregulation of COX-2 and PGE 2 characterize the transition of DC from immature to ma-(23,66). In addition, TNF-α has been shown to be a critture stages, namely the upregulation of antigen presentaical modulator of NF-κB, and there is evidence that tion/costimulatory molecule expression, the ability to MSCs can express TNF receptor (TNFR) (14). Recently, present defined antigens, and the capacity to migrate to Nemeth et al. reported that MSCs, when activated by CCL19 (24). Furthermore, reduction of IL-12 secretion LPS or TNF-α, could reprogram macrophages by releaswas also observed after MSC coculture (39) .
ing PGE 2 that acts on the macrophages through EP2 and MSCs produce several cytokines, including IL-6 and EP4 receptors, for the treatment of sepsis (66,71). These monocyte-colony stimulating factor (M-CSF), which findings suggest that NF-κB activation via both TLR have been shown to have an important role in DC differand TNFR expressing on MSCs can suppress T-cell proentiation (65) . It is now clear that modulation of DC liferation and DC maturation ( Fig. 1) . maturation by MSC requires IL-6 and a contact-dependent signal (20,24). Djouad et al. observed that MSCs HOMING OF EXOGENOUS MSCs secrete higher levels of IL-6, which was involved in the Homing is the process by which cells migrate to, and reversion of the maturation of DC to a less mature pheengraft in, the tissue in which they can exert local, funcnotype and in the partial inhibition of bone marrow protional effects. While the homing of leukocytes to sites genitors to DC (20) . PGE 2 has also been observed to of inflammation is well studied (35, 54) , the mechanisms contribute to the modulation of DC maturation (12, 20) . of progenitor cell homing to sites of ischemia or injury Chen et al. (12) demonstrated that blockade of PGE 2 are poorly understood. Yet, we will describe the lessons synthesis in MSCs could revert most of the inhibitory learned from leukocyte homing to provide insight into effects on DCs differentiation and function. Taken to-MSC transplantation (Fig. 2) . gether, these findings suggest that PGE 2 
and IL-6 can Homing involves a cascade of events initiated by mediate DC maturation by MSCs and that leads to Tshear resistant adhesive interactions between flowing cell suppression. cells and the vascular endothelium at the target tissue MSCs Induce T-Cell Suppression Through Nuclear (Step 1). This process is mediated by "homing recep-Factor-κB (NF-κB) Pathway
tors" expressed on circulating cells that engage relevant endothelial coreceptors, resulting in cell tethering and Toll-like receptors (TLRs) are conserved family receptors that recognize pathogen-associated molecular rolling contacts on the endothelial surface. This is typically followed by chemokine-triggered activation of in-patterns and promote the activation of immune cells (104) . It is recognized that TLRs mediate stress re-tegrin adhesiveness (Step 2), firm adhesion (Step 3) and extravasation (Step 4) (81). The cellular expression of sponses of bone marrow-derived progenitor cells (64) . A recent study described the importance of TLRs in mi-adhesion molecules is critically important for cell-based therapy to mediate adhesion of the implanted cells to the gration and immune regulation of MSCs (71, 97) . The common signaling feature among all TLRs is the activa-extracellular matrix of targeted tissue in host animals (37) . The homing of MSC after systemic or local infu-tion of the transcription factor (NF-κB), which has been sion has been studied in animal models in a variety of tion has been studied to regulate T cell and natural killer cell trafficking (103). experimental settings. A growing number of studies of various pathologic conditions have demonstrated that
The expression of integrins has been known to contribute to the process of neutrophil locomotion, includ-MSC selectively home to sites of injury, irrespective of the tissue (68, 76) . The homing ability of MSC has been ing members of integrin β1 and β2 (35, 102) . Integrin β1 also involves cell-to-cell adhesion (102), which may be demonstrated in the settings of wound healing, and tissue regeneration (58) . Because most of the studies have important for the anchorage of the engrafted cells. The process of the integrin expression is enhanced upon leu-been investigated by systemic infusion of MSCs for clinical application, the understanding of homing mech-kocyte activation by chemokines leading to integrinmediated firm adhesion on endothelial cell monolayers, anisms might be crucial for enhancing MSC engraftment particularly when cells are infused via the vascular route.
diapedesis through the endothelial cell wall, and finally the migration/invasion into the extracellular matrix us-Integrins and MSC Homing ing integrin-dependent processes and matrix-degrading proteases (35) . Stimulated by a chemotactic gradient, Integrins have been known to play a key role in cell adhesion, migration, and chemotaxis (35, 75, 102) . Among leukocytes traverse the extracellular matrix by way of transient interactions between integrin receptors and the family of integrins, integrin α4/β1 is a cell surface heterodimer, which mediates cell-cell and cell-extracel-components of the extracellular matrix that serve as adhesive ligands (48, 69) . As expected, blockade of inte-lular matrix interactions through adhesion to the vascular cell adhesion molecule (VCAM)-1 and to the V-region grin β1 diminishes neutrophil migration to the lung during inflammation (75). of fibronectin (31) . This integrin α4/β1-VCAM interac-VCAM-1 has been shown to promote the adhesion of enhance integrin α4β1-expressing cell binding, allowing them to adhere to and forcefully contract the surround-endothelium, lymphocytes, monocytes, and DCs (92, 96). Primarily, VCAM-1 is an endothelial ligand for in-ing matrix (99). These reports support a notion that integrin α4/β1-fibronectin interaction plays a major role in tegrins α4β1, β1, and α4β7. Upregulation of VCAM-1 by endothelial cells due to cytokines occurs as a result transmigration of MSCs into extracellular matrix (Fig. 2C) . of increased gene transcription in response to TNF-α CXCR4 Expression on MSC and Interaction and IL-1β (105) .
Stimulation of leukocyte adhesion to
With Stromal Cell- Derived Factor 1 (SDF-1 ) the endothelium is one of many TNF-α activities and is coordinated with the upregulation of adhesion molecules SDF-1, which is officially designated chemokine (C-X-C motif) ligand 12 (CXCL12), is a small chemotactic on the endothelial cell surface (57) . A recent study demonstrated that anti-VCAM-1 antibodies reduce the adhe-cytokine that activates leukocytes and is often induced by proinflammatory stimuli such as TNF-α or IL-1 (27) . sion of rat MSCs to microvascular endothelial cells (85) .
It has been demonstrated that bone marrow-derived The receptor for this chemokine is CXCR4 and the SDF-1-CXCR4 interaction is considered to be exclusive (56) . MSCs expressed many integrins on their surface (17), including high levels of integrin β1 and α4, and their However, Bleul et al. suggested that because SDF-1 is expressed constitutively in a broad range of tissues it binding partners were upregulated in the ischemic myocardium (36) . Ip et al. (36) demonstrated that a signifi-may have a role in immune surveillance and in basal extravasation of lymphocytes and monocytes rather than cant reduction in the total number of MSC in the infarcted myocardium was observed after integrin β1 solely in inflammation (8) . This interaction between SDF-1 and its ligand CXCR4 plays an important role in blockade. Also some studies revealed that the integrin α4/β1 is one of the integrins that can mediate initial homing as shown by studies on engraftment of hematopoietic stem/progenitor cells (70) and on colonization of capture, rolling, and firm attachment of MSCs to the bone marrow (37). Ruster et al. (78) showed that MSCs bone and bone marrow by metastatic breast and prostate cancer cells (63) . SDF-1, required for stem cell homing interact in a coordinated fashion with endothelial cells, not only by integrin α4/β1-VCAM-1 interaction or inte-to bone marrow, was upregulated immediately after myocardial infarction and downregulated within 7 days. grin β1, but also by the endothelial phenotype, P-selectin, MMP-2 secretion, and cytokines. The requirement Askari et al. (2) concluded by these findings that SDF-1 was sufficient to induce therapeutic stem cell homing of integrin α4 for bone marrow engraftment of stem cells has been substantiated in other studies where mu-to injured myocardium and suggest a strategy for directed stem cell engraftment into injured tissues. rine or sheep bone marrow was incubated with anti-integrin α4 antibody and the repopulating stem cells failed Sordi et al. reported the chemotactic responsiveness of MSCs to chemokines. MSCs released chemokines to engraft in bone (108). The expression of several adhesion molecules modulate the homing of MSCs to endo-and displayed a restricted response pattern to chemokines. MSCs migrated appreciably in response to SDF-thelial cells as demonstrated by coculture experiments (94) , a flow chamber model (78) , and an intra-arterial 1 and CX3CL, consistent with their expression of chemokine receptors CXCR4 or CX3CR1, respectively. Based injection (85) ( Fig. 2A) . on these data, they stated that the SDF-1-CXCR4 axis
MSC Interactions With Extracellular Matrix Components
is involved in MSC migration and this is conserved also in tissue MSCs (88) . Also Wynn et al. (106) showed Fibronectin binds extracellular matrix components such as collagen, fibrin, and heparan sulfate proteogly-that CXCR4 is important for MSC migration to bone marrow. However, cell surface receptor levels of CXCR4 cans (77) . It plays a major role in cell adhesion, growth, migration, and differentiation, and it is important for on MSC is low, with large amounts found intracellularly. Although CXCR4 is present at the cell membrane wound healing processes (99). Along with fibrin, plasma fibronectin is deposited at the site of injury to form a of 3.9% of MSCs, high levels of receptor expression were found in 83% to 98% of cells intracellularly. This blood clot that stops bleeding and protects the underlying tissue. As repair of the injured tissue continues, fi-was in contrast to CD34 + cells, in which only 12.2% of the cells were positive as previously published (43) . broblasts and macrophages begin to remodel the area, degrading the proteins that form the provisional blood CXCR4 intracellular storage has been previously described in response to cytokines (101) . In the study, the clot matrix and replacing it with a matrix that more resembles the normal, surrounding tissue (93). Fragment-response of the CXCR4 receptor to SDF-1 was shown in dose-dependent manner. Thus, the CXCR4 receptor, ing fibronectin further exposes its V-region, which contains the site for integrin α4β1 binding, which is expressed which is present at low levels at the cell surface, is likely to be translocated to the surface upon chemokine stimu-on MSCs. These fragments of fibronectin are believed to lation and contributes to MSC migration (106) (Fig. 2B) . jured tissues might depend on the systemic and local inflammatory state (73) . However, there are several studies that contradict these results. One report stated that MSCs lack many Cancer and MSCs effectors of homing, especially E-selectin ligands and CXCR4 (82) . Another study indicated that MSCs use
Recently MSCs have been found to have a central role in the pathogenesis and progression of tumors. Be-integrin β1 but not CXCR4 for myocardial migration and engraftment (36) . Taken together, the mechanism of cause there is evidence that tumors can be considered sites of potential inflammatory cytokine and chemokine MSC migration is still unclear and further investigation is required.
production, these properties may enable MSC to home to, and immunomodulate, the tumor environment (32) .
Other Factors Modulating MSC Migration
One of the distinct compartments of generalized solid tumors is the stroma, which is the nonmalignant support-Basic Fibroblast Growth Factor (bFGF). Large stores ive tissue that includes extracellular matrix, blood vesof bFGF are typically embedded in extracellular matrix sels, immune and inflammatory cells, and connective tismolecules. bFGF was able to increase the migratory acsue (50) . Stroma is placed between malignant cells and tivity of MSCs by activation of the Akt (protein kinase normal host tissues and is crucial for tumor growth. Re-B) pathway. Surprisingly, bFGF could have opposing cent evidence showed that MSCs actively migrate to, effects on MSC migration depending on the concentraand proliferate in, tumors. MSCs were found to contribtion. Gradient experiments using bFGF showed that low ute to the tumor-associated stroma within sites of inconcentrations of bFGF led to an attraction of the cells, flammation and were in close proximity with tumor cells whereas higher concentrations resulted in repulsion.
as part of the remodeling process (42). Homing and mi-This ambivalent effect of bFGF provides the possibility gration of MSCs to tumors was found to be mediated by of purposeful routing of MSCs (84 including IL-8, TGF-β, and VEGF (6) . The incorporaalso showed that transendothelial migration of MSCs is tion of MSC into an otherwise nonmalignant cell mass at least partially regulated by MMP-2 (94) . may lead to metastatic growth as observed in a breast TLR-Mediated Migration. We previously described tumor implants (42). TLR signaling in the context of MSC differentiation into CONCLUSIONS AND FUTURE PERSPECTIVES immunosuppressive cells. TLR-mediated differentiation may also prime the cells to migrate. Using transwell mi-
The objective of this review was to provide a clear gration assays, TLR ligation promoted human MSC miand unified theory of MSC therapy from initial injection gration and disruption of TLRs by neutralizing antibodto therapeutic response. It is clear that MSCs have a ies compromised MSC migration (97). capacity to home and integrate into damaged tissues and provide immunomodulatory effects by paracrine and/or The Global Role of Inflammation and MSC Homing cell-cell contact that is regulated by the inflammatory microenvironment. This approach is now being success-It is likely that increased inflammatory chemokine concentration at the site of inflammation is a major fac-fully used to cotransplant MSCs with other parenchymal cells, such as hepatocytes or islet cells, to enhance the tor causing MSCs to preferentially migrate to these sites. Chemokines are released after tissue damage and MSC engraftment and function of parenchymal cells in an immunoprotected fashion (40,46). These findings may ex-express the receptors for several chemokines (28) . The migration capacity of MSCs was found to be under the tend future prospects of the clinical application of MSCs into broader applications. Furthermore, the opportunity control of a large range of receptor tyrosine kinase growth factors such as platelet-derived growth factor exists to use genetic engineering of MSCs to express specific factors for homing and therapy (82) . In sum-(PDGF) or insulin-like growth factor 1 (IGF-1) and chemokines such as CCR2, CCR3, CCR4, or CCL5 as mary, a rational understanding of MSCs mechanisms of action will allow for the translation of our basic knowl-assessed by in vitro migration assays. In addition, most chemokines are more effective when stimulated by edge of MSC biology into the design of new clinical therapies. Ongoing and future clinical trials with MSCs TNF-α or IL-1β. These findings suggested that the mobilization of MSCs and their subsequent homing to in-will provide a rich resource of bedside information that 14. Crisostomo, P. R.; Wang, M.; Herring, C. M.; Markel, can be studied extensively in the laboratory to further T. A.; Meldrum, K. K.; Lillemoe, K. D.; Meldrum, advance this burgeoning field. D. R. Gender differences in injury induced mesenchymal stem cell apoptosis and VEGF, TNF, IL-6 expression:
